Theriva Biologics Inc.

1.70
-0.02 (-1.16%)
At close: Feb 14, 2025, 3:59 PM
undefined%
Bid 1.66
Market Cap 4.73M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -32.59
PE Ratio (ttm) -0.05
Forward PE n/a
Analyst Buy
Ask 1.71
Volume 56,613
Avg. Volume (20D) 474,613
Open 1.71
Previous Close 1.72
Day's Range 1.67 - 1.72
52-Week Range 1.14 - 17.00
Beta undefined

About TOVX

Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and...

Industry Biotechnology
Sector Healthcare
IPO Date Dec 18, 2006
Employees 22
Stock Exchange AMEX
Ticker Symbol TOVX

Analyst Forecast

According to 1 analyst ratings, the average rating for TOVX stock is "Buy." The 12-month stock price forecast is $6, which is an increase of 252.94% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts
1 month ago
+35.38%
Theriva Biologics shares are trading higher after ... Unlock content with Pro Subscription
1 month ago
+14.04%
Theriva Biologics shares are trading higher after the company announced it received a notice of allowance for U.S. Patent Application No. 18.534,962 titled "Microbiome Protection from Oral Antibiotics."